Top Markets
Coin of the day
BridgeBio Oncology Therapeutics Inc. BridgeBio Oncology Therapeutics Inc.

BridgeBio Oncology Therapeutics Inc.

BBOT
Rankning i aktier #11443
BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical... BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initiatives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer.
Aktiekurs
$8.74
Senast synkroniserad: 2026-08-28
Marknadsvärde
$699.74M
Förändring (1 dag)
-4.85%
Förändring (1 år)
-2.29%
Land
US
Handel BridgeBio Oncology Therapeutics Inc. (BBOT)

Kategori

P/B-tal för BridgeBio Oncology Therapeutics Inc. (BBOT)
P/B-tal per 2026 TTM: 0
Enligt BridgeBio Oncology Therapeutics Inc. senaste finansiella rapporter och aktiekurs är det aktuella P/B-talet (TTM) 0. I slutet av 2026 hade företaget ett P/B-tal på 0.
Historik för P/B-tal för BridgeBio Oncology Therapeutics Inc. från 2026 till 2026
P/B-tal vid årets slut
År P/B-tal Ändra
Inte tillräckligt med data för de angivna datumen.
P/B-tal för liknande företag eller konkurrenter
Företag P/B-tal Skillnad i P/B-tal Land
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
3.7087 -
US
- -
CH